The mechanism of ruscogenin to inhibit AKI is by decreasing the expression of Rev-erbα/β, increasing intracellular HO-1 and Slc7a11 levels, and ultimately inhibiting cellular iron death. Here, SLC7A11 is linked to acute kidney injury.